Search Results

AbbVie's office in South San Francisco, California

Layoffs

AbbVie Ends 11-Year Relationship With Calico, Lays Off 100+

In January, AbbVie and Calico’s fosigotifator failed to show significant signs of efficacy in the HEALEY ALS platform trial for amyotrophic lateral sclerosis.

November 13, 2025

·

2 min read

·

Tristan Manalac

Press Releases

Calico Appoints Joseph R. Arron, M.D., Ph.D., as Head of Human Biology and Genetics

February 5, 2026

·

3 min read

Creative sketch collage of business people handshake gesture approval project development success colleagues cooperation support.

Collaboration

Alphabet Subsidiary Calico Colors In Up To $570M+ Aging Deal With China’s Mabwell

Calico will leverage 9MW3811’s anti-inflammatory mechanism to advance its mission of addressing aging-related diseases.

June 27, 2025

·

2 min read

·

Tristan Manalac

Press Releases

Calico Appoints Philip R. Kym, Ph.D., as Head of Drug Discovery

October 17, 2025

·

3 min read

Press Releases

Calico Life Sciences Announces U.S. FDA Orphan Drug Designation for Investigational Treatment of Autosomal Dominant Polycystic Kidney Disease

November 6, 2025

·

2 min read

Press Releases

Calico Life Sciences Announces U.S. FDA Fast Track Designation for Investigational Treatment of Autosomal Dominant Polycystic Kidney Disease

October 3, 2025

·

2 min read

Conceptual business illustration of upcoming business problem metaphor with falling domino and businessman silhouette. Minimalistic vector eps 10 illustration

ALS

HEALEY ALS Trial Serves Up More Disappointment as Denali, AbbVie/Calico Fail

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the latest setbacks for the controversial platform trial, the results from which have largely mirrored the dismal success rate in ALS overall.

January 10, 2025

·

5 min read

·

Heather McKenzie

Biotech Bay

Calico Life Sciences Announces that Fosigotifator (ABBV-CLS-7262) for Vanishing White Matter Disease has been Selected for the FDA START Pilot Program

Calico Life Sciences LLC today announced that its investigational eIF2B activator fosigotifator (ABBV-CLS-7262) has been accepted into the U.S. Food and Drug Administration (FDA) Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program.

June 7, 2024

·

3 min read

From left: Terray CEO Jacob Berlin, Ph.D and CFO a

Business

Terray and Calico Strike Biotech’s Latest R&D Deal Against Age-Related Diseases

Terray Therapeutics and Calico Life Sciences struck a research and development collaboration focused on the development of small-molecule therapeutics for age-related diseases.

October 12, 2022

·

3 min read

·

Alex Keown

Drug Development

Calico Life Sciences Announces First Participant Dosed in Phase 1b Clinical Study Evaluating ABBV-CLS-7262 for the Treatment of Vanishing White Matter Disease

Calico Life Sciences LLC today announced that the first participant has been dosed in a Phase 1b clinical trial, (study M23-523; NCT05757141), evaluating the investigational eIF2B activator ABBV-CLS-7262 as a potential treatment for Vanishing White Matter (VWM) disease.

April 26, 2023

·

4 min read